Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 4/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930301 | 1.00 | MAPK1 (0.54) | MAPK1CNR1CHEK1GABRA5ATR | |
| SCHEMBL2926014 | 0.87 | MAPK1 (0.52) | MAPK1CHEK1ATRNEK2PRKDC | |
| SCHEMBL2933636 | 0.80 | MKNK1 (0.52) | MAPK1GABRA5ATR | |
| SCHEMBL2931488 | 0.76 | NEK2 (0.64) | CHEK1ATRNEK2PRKDCATM | |
| SCHEMBL6696482 | 0.75 | PIK3CG (0.55) | MAPK1CHEK1ATRNEK2PRKDC | |
| SCHEMBL2936756 | 0.74 | ATR (0.62) | ATR | |
| SCHEMBL2930631 | 0.73 | ACVR2A (0.57) | CHEK1ATRPRKDCATMUSP7 | |
| SCHEMBL15201514 | 0.72 | ATR (0.58) | MAPK1CHEK1ATRNEK2PRKDC | |
| SCHEMBL2931257 | 0.72 | ATR (0.46) | CHEK1ATRNEK2USP7 | |
| SCHEMBL2934942 | 0.71 | ALDH1A1 (0.53) | MAPK1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | MAPK1 255/4885CNR1 1076/4885CHEK1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.